Corporate GovernanceMay 4, 2026, 04:06 PM
STAAR Surgical Terminates Alcon Merger, Resets Strategy
AI Summary
STAAR Surgical Company announced the termination of its merger agreement with Alcon in January 2026 following shareholder rejection, leading to a significant corporate reset. The company expanded its Board to seven directors, appointing three new members, and transitioned to an Interim Co-Chief Executive Officer structure. STAAR outlined its 2026 strategic imperatives focused on renewed revenue growth, improved profitability, and accelerated innovation, building on recent operational successes like the EVO+ launch in China and expanded EVO indications.
Key Highlights
- Alcon merger agreement terminated in January 2026 after STAAR shareholders voted against the proposal.
- Board expanded to seven directors, with Neal C. Bradsher, Richard T. LeBuhn, and Christopher M. Wang appointed in January 2026.
- Stephen C. Farrell's employment as CEO terminated January 31, 2026; Warren Foust and Deborah Andrews appointed Interim Co-CEOs.
- Surpassed 4 million Implantable Collamer Lenses sold globally in February 2026, two years after 3 million milestone.
- EVO+ launched in China in December 2025 with early demand exceeding expectations.
- US FDA approved an expanded age indication for EVO (now 21-60); Brazil also approved an expanded indication range.
- 2026 Strategic Imperatives focus on expanding revenue, improving profit, and accelerating innovation.
- 2024 annual cash bonus plan funded at 0% for executives; 2025 annual cash bonus plan funded at 140%.